Also at one year, no specific patient background factors predicting jakinib continuation were found. These results show that—although this was a small number of retrospectively evaluated patients—patients with difficult-to-treat RA may be effectively treated with the jakinibs baricitinib and tofacitinib, regardless of background demographics or disease parameters. The authors note that switching between jakinibs and the use of other jakinibs require further investigation.
You Might Also Like
Also By This Author
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
- Kamiya M, Togawa D, Mori S, et al. Efficacy of janus kinase inhibitors for difficult-to-treat RA in clinical practice [abstract POS0088]. Ann Rheum Dis. 2021 Jun;80(suppl 1):252–253.
- Nagy G, Roodenrijs NMT, WEsing PMJ, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jun;80(1):31–35.